Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Equity

v3.25.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period (in shares) at Mar. 31, 2022   33,364,722              
Balance, beginning of period at Mar. 31, 2022 $ 399,204 $ 33 $ 234,549 $ 0 $ 203,528 $ (38,906)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             38,137 40,923 64,294
Stock compensation expense 5,954   5,954            
Repurchase of employee stock units on vesting (643)   (643)            
Net income 33,666       33,666        
Foreign currency translation adjustment (19,202)         (19,202)      
Other 9       1 8      
Balance, end of period (in shares) at Mar. 31, 2023   33,508,076              
Balance, end of period at Mar. 31, 2023 418,988 $ 33 239,860 0 237,195 (58,100)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             22,829 98,177 101,161
Stock compensation expense 5,754   5,754            
Repurchase of employee stock units on vesting $ (2,058)   (2,058)            
Repurchase of shares under authorized program (in shares) (8,018) (8,018)              
Repurchase of shares under authorized program $ (250)     (250)          
Net income 51,588       51,588        
Foreign currency translation adjustment 836         836      
Other $ 29 $ 1 (1)     29      
Balance, end of period (in shares) at Mar. 31, 2024 33,722,225 33,722,225              
Balance, end of period at Mar. 31, 2024 $ 474,887 $ 34 243,555 (250) 288,783 (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options (in shares) 33,573 33,573              
Issuance of common stock in exercise of stock options $ 632   632            
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             21,802 72,013 87,782
Stock compensation expense 5,244   5,244            
Repurchase of employee stock units on vesting $ (3,230)   (3,230)            
Repurchase of shares under authorized program (in shares) (694,025) (694,025)              
Repurchase of shares under authorized program $ (20,138)     (20,138)          
Net income 53,515       53,515        
Foreign currency translation adjustment (15,515)         (15,515)      
Other $ (80) $ (1)       (79)      
Balance, end of period (in shares) at Mar. 31, 2025 33,243,370 33,243,370              
Balance, end of period at Mar. 31, 2025 $ 495,315 $ 33 $ 246,201 $ (20,388) $ 342,298 $ (72,829)